Track papers across labs, topics, and trends.
Search papers, labs, and topics across Lattice.
The paper introduces CovAngelo, a hybrid quantum-classical computing platform for modeling chemical reactions, specifically ligand-protein binding in drug discovery, using a novel quantum-in-quantum-in-classical (QM/QM/MM) multiscale embedding model. This model integrates molecular dynamics with quantum-information-enhanced density matrix embedding theory and quantum chemistry solvers, leveraging quantum-information metrics to generate entanglement-consistent orbitals for high-accuracy description of strongly correlated regions. The platform's ability to accurately estimate reaction barriers at reduced computational cost, demonstrated through modeling zanubrutinib docking to Bruton's tyrosine kinase, shows promise for improving drug discovery pipelines by reducing false positives and negatives.
Quantum computers could slash drug discovery simulations by 20x, thanks to a new hybrid platform that accurately models complex chemical reactions.
We present a computational platform for modeling chemical reactions in complex molecular environments, focused on ligand-protein binding in drug discovery. The platform implements our new quantum-in-quantum-in-classical (QM/QM/MM) multiscale embedding model that integrates molecular dynamics with a quantum-information-enhanced density matrix embedding theory and quantum chemistry solvers, including explicit solvent. Quantum-information metrics are utilized to generate entanglement-consistent orbitals, enabling a high-accuracy description of strongly correlated regions. The framework supports multiple computational backends, including multi-CPU, NVIDIA multi-GPU architectures, and quantum hardware (IQM, IonQ, IBM) integrated under CUDA-Q, and is designed for compatibility with future fault-tolerant quantum systems. The new platform's capabilities are demonstrated by modeling covalent docking of zanubrutinib to Bruton's tyrosine kinase via a Michael addition mechanism, computing the full reaction energy profiles and energy barriers at a reduced computational cost relative to existing methods. As a 2nd-generation anticancer agent, zanubrutinib serves as a proof of concept for covalent inhibitor discovery. Accurate first-principles reaction barrier estimations provided by our method can contribute to reducing false positive and negative rates in drug discovery pipelines. Scalability is validated through benchmarks on GPU clusters, cloud-based CPU infrastructures. We demonstrate integration with quantum devices (up to 20 qubits), alongside resource estimates for fault-tolerant quantum computing, indicating potential speedups of up to 20x. Beyond single reactions, the platform supports the construction of reaction networks in chemical metric space, facilitating ligand screening and systematic exploration of reactive pathways.